During the past decade, Carolina Blood and Cancer Care Associates PA-Lancaster conducted 24 clinical trials. In the 10-year time frame, 24 clinical trials started and 30 clinical trials were completed, i.e. on average, 125% percent of trials that started reached the finish line to date. In the past 5 years, 7 clinical trials started and 20 clinical trials were completed. i.e. 285.7% of trials that started reached the finish line.

Out of the total clinical trials conducted in "Carolina Blood and Cancer Care Associates PA-Lancaster" #1 sponsor was "National Cancer Institute (NCI)" with 11 trials, followed by "SWOG Cancer Research Network" with 10 trials sponsored, "Alliance for Clinical Trials in Oncology" with 9 trials sponsored, "Novartis Pharmaceuticals" with 3 trials sponsored and "Spectrum Pharmaceuticals, Inc" with 3 trials sponsored. Other sponsors include 18 different institutions and companies that sponsored additional 28 trials in total.

In terms of collaborators to trials, out of the total clinical trials conducted in "Carolina Blood and Cancer Care Associates PA-Lancaster" #1 collaborator was "National Cancer Institute (NCI)" with 22 trials as a collaborator, "NRG Oncology" with 3 trials as a collaborator, "Canadian Cancer Trials Group" with 2 trials as a collaborator, "Acceleron Pharma Inc. (a wholly owned subsidiary of Merck Sharp and Dohme, a subsidiary of Merck & Co., Inc.)" with 1 trials as a collaborator and "Astellas Pharma US, Inc." with 1 trials as a collaborator. Other collaborators include 5 different institutions and companies that were collaborators in the rest 15 trials.

According to Clinical.Site data, the most researched conditions in "Carolina Blood and Cancer Care Associates PA-Lancaster" are "Breast Cancer" (12 trials), "Recurrent Squamous Cell Lung Carcinoma" (6 trials), "Stage IV Squamous Cell Lung Carcinoma AJCC v7" (4 trials), "Cancer" (3 trials) and "Acute Myeloid Leukemia" (2 trials). Many other conditions were trialed in "Carolina Blood and Cancer Care Associates PA-Lancaster" in a lesser frequency.

Most popular intervention types in "Carolina Blood and Cancer Care Associates PA-Lancaster" are "Drug" (46 trials), "Other" (32 trials), "Biological" (9 trials), "Procedure" (5 trials) and "Radiation" (5 trials). Other intervention types were less common.

The name of intervention was led by "Laboratory Biomarker Analysis" (16 trials), "placebo" (8 trials), "Docetaxel" (7 trials), "Quality-of-Life Assessment" (7 trials) and "Cyclophosphamide" (4 trials). Other intervention names were less common.

The vast majority of trials in "Carolina Blood and Cancer Care Associates PA-Lancaster" are 46 trials for "All" genders, 12 trials for "Female" genders and 1 trials for "Male" genders.

Currently, there are NaN active trials in "Carolina Blood and Cancer Care Associates PA-Lancaster". undefined are not yet recruiting, 8 are recruiting, 19 are Active, not recruiting, and undefined are Enrolling by invitation. In total, there were 25 completed trials in Carolina Blood and Cancer Care Associates PA-Lancaster, undefined suspended trials, and 5 terminated clinical trials to date.

Out of the total trials that were conducted in Carolina Blood and Cancer Care Associates PA-Lancaster, 3 "Phase 1" clinical trials were conducted, 12 "Phase 2" clinical trials and 38 "Phase 3" clinical trials were conducted as well. "Phase 4" trials included 0 trials, and there were also 1 trials that are defined as “Not Applicable".